GlassScriptPhysician profile
Janet Moran
NPI 1356080758
$1,488.65
in general payments reported to CMS, 2019-2025
20 companies · $30.39 in 2025
The $30.39 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $601 · 2023: $766 · 2024: $91.39 · 2025: $30.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.68 | 2022-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $171.28 | 2022-2023 | |
| Novo Nordisk INC | $135.93 | 2022-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $133.19 | 2022-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $93.10 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $85.81 | 2022-2023 | |
| Lilly USA, LLC | $81.66 | 2022-2024 | Mounjaro, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.80 | 2023-2024 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $72.55 | 2022-2023 | Breztri |
| Antares Pharma, INC. | $72.04 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $42.27 | 2023-2024 | |
| Astellas Pharma US INC | $33.13 | 2023 | Veozah |
| Boston Scientific Corporation | $30.39 | 2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $29.10 | 2023 | Opsumit, Uptravi |
| Lucid Diagnostics INC. | $29.04 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.92 | 2023 | Jot Dx |
| Sumitomo Pharma America, INC. | $17.89 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $17.85 | 2023 | Rexulti |
| Azurity Pharmaceuticals, INC. | $13.85 | 2023 | Edarbi |
| Amgen INC. | $13.17 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.